Citadel Advisors
KITE

Citadel Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Citadel Advisors’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-72,300
Closed -$13M – 8820
2017
Q3 		$13M Buy
72,300
+30,500
+73% +$4.25M 0.01% 1386
2017
Q2 		$4.33M Buy
41,800
+5,600
+15% +$457K ﹤0.01% 2275
2017
Q1 		$2.84M Buy
36,200
+2,600
+8% +$161K ﹤0.01% 2651
2016
Q4 		$1.51M Sell
33,600
-400
-1% -$19.6K ﹤0.01% 3298
2016
Q3 		$1.9M Buy
34,000
+17,200
+102% +$958K ﹤0.01% 3025
2016
Q2 		$840K Sell
16,800
-8,000
-32% -$393K ﹤0.01% 3782
2016
Q1 		$1.14M Buy
24,800
+5,200
+27% +$252K ﹤0.01% 3331
2015
Q4 		$1.21M Sell
19,600
-12,900
-40% -$908K ﹤0.01% 3353
2015
Q3 		$1.81M Buy
32,500
+18,200
+127% +$1.14M ﹤0.01% 3071
2015
Q2 		$872K Sell
14,300
-11,800
-45% -$673K ﹤0.01% 4154
2015
Q1 		$1.5M Buy
26,100
+18,200
+230% +$1.22M ﹤0.01% 3431
2014
Q4 		$456K Buy
+7,900
New +$333K ﹤0.01% 4848

Citadel Advisors's KITE Position: Q3 2017 in Review

Citadel Advisors sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 27,170 shares — an estimated $3.79M sold.

Citadel Advisors first reported a position in KITE in Q2 2014 and held it in 13 quarters. The position peaked at $34.5M in Q1 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Citadel Advisors reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 27,170 Kite Pharma, Inc. shares in Q3 2017, an estimated $3.79M.
  • Citadel Advisors first reported a position in Kite Pharma, Inc. in Q2 2014 and held it in 13 quarters.
  • Citadel Advisors's Kite Pharma, Inc. position peaked at $34.5M in Q1 2016.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.